http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
중등도-중증의 한국인 건선 환자에서 Ustekinumab 장기 투여에 따른 효과 및 안전성 연구
김연아 ( Yeona Kim ),배경남 ( Kyung-nam Bae ),손진화 ( Jin-hwa Son ),신기혁 ( Kihyuk Shin ),김훈수 ( Hoonsoo Kim ),고현창 ( Hyun-chang Ko ),김문범 ( Moon-bum Kim ),신봉석 ( Bong Seok Shin ),김병수 ( Byungsoo Kim ) 대한피부과학회 2022 대한피부과학회지 Vol.60 No.3
Background: Ustekinumab is a humanized monoclonal antibody targeting interleukin (IL)-12 and IL-23. Although popular, data on its long-term efficacy and safety in Korean patients with psoriasis are limited. Objective: To evaluate the long-term efficacy and safety of ustekinumab in Korean patients with psoriasis. Methods: A retrospective study in patients with moderate-to-severe psoriasis who had been treated with ustekinumab for at least 5 years was conducted. The sex, age, body mass index, medical records, previous psoriasis therapy, psoriasis area and severity index (PASI) scores, and adverse events were evaluated. Results: Twenty-five patients (median age 47.00 years) had been treated with ustekinumab for 5 years. The mean duration of psoriasis was 19.12±8.45 years, and the treatment duration with ustekinumab was 285.12±8.48 weeks. The baseline PASI was 17.52±7.38. PASI75 was achieved in 84% of the patients at week 28, and 96% of the patients maintained PASI75 during the 5-year follow-up period. Furthermore, 56% of patients reached PASI90 at 28 weeks, and 48% of patients maintained PASI90 for 5 years. No unexpected adverse events other than herpes zoster, herpes simplex, or elevated liver enzymes were reported. Conclusion: Ustekinumab demonstrated long-lasting efficacy with an acceptable safety profile in Korean patients with moderate-to-severe psoriasis. (Korean J Dermatol 2022;60(3):151∼158)
여성형탈모에서 저용량 경구 미녹시딜의 효과 및 안정성: 44명의 환자를 대상으로 한 단일기관 연구
김영범 ( Youngbeom Kim ),이기욱 ( Giwook Lee ),신준오 ( Jun-oh Shin ),노동영 ( Dong Young Roh ),김연아 ( Yeona Kim ),원상현 ( Sang-hyeon Won ),이정수 ( Jungsoo Lee ),신기혁 ( Kihyuk Shin ),김훈수 ( Hoonsoo Kim ),고현창 ( Hyun-chan 대한피부과학회 2024 대한피부과학회지 Vol.62 No.3
Background: Female-pattern hair loss (FPHL) is characterized by diffuse hair thinning in the mid-frontal scalp and increased hair shedding. Although the use of low-dose oral minoxidil (LDOM) is increasing significantly in Korea, data on its use are limited. Objective: To determine the efficacy and safety of LDOM in Korean patients with FPHL. Methods: This retrospective, single-center study was conducted at Pusan National University Hospital. The study included female patients with pattern hair loss who received treatment with LDOM at 1.25 mg/d for a minimum of 6 months in combination with other treatments. Patients were eligible for LDOM addition if their previous treatments showed a limited response and the previous treatment regimen remained unchanged throughout the evaluation period. Clinical response to treatment was evaluated using the Sinclair hair loss severity scale. Results: The study included 44 females with FPHL. Before treatment, the mean Sinclair scale score was 2.77, which decreased to 2.27 after treatment. By the 3rd month, one patient (2.3%) experienced worsening, while seven patients (15.9%) showed slight improvement. By the 6th month, the treatment response was as follows: stabilization in 30 patients (68.2%), slight improvement in 13 patients (29.5%), and substantial improvement in one patient (2.3%). Adverse effects, predominantly hypertrichosis, were observed in nine patients. All adverse effects improved upon discontinuation of LDOM and no life-threatening adverse effects were observed during the study. Conclusion: This study provides evidence that LDOM can be an effective therapeutic option with a good safety profile for FPHL. (Korean J Dermatol 2024;62(3):136∼142)
김종욱 ( Jongwook Kim ),이기욱 ( Giwook Lee ),신준오 ( Jun-oh Shin ),노동영 ( Dong Young Roh ),김연아 ( Yeona Kim ),원상현 ( Sang-hyeon Won ),이정수 ( Jungsoo Lee ),신기혁 ( Kihyuk Shin ),김훈수 ( Hoonsoo Kim ),고현창 ( Hyun-chang 대한피부과학회 2024 대한피부과학회지 Vol.62 No.3
Congenital smooth muscle hamartoma is a benign proliferation of smooth muscles within the dermis. The classic form presents as well-defined, skin-colored, or hyperpigmented plaques associated with hypertrichosis. However, there have been reports of atypical forms, including a follicular spotted appearance, linear atrophic plaques, and morphea-like forms. In such cases, distinguishing congenital smooth muscle hamartomas from other cutaneous diseases can be challenging. Herein, we report on a 16-month-old boy who presented with a hypopigmented patch and hypertrichosis on his back since birth. Histopathological examination revealed mild acanthosis and well-defined smooth muscle bundles haphazardly oriented in the dermis. These bundles stained positively with Masson’s trichrome stain. Based on these findings, a definitive diagnosis of congenital smooth muscle hamartoma was established. In conclusion, an exceptionally rare case of congenital smooth muscle hamartoma with a hypopigmented appearance is reported. (Korean J Dermatol 2024;62(3):165∼168)
전기외과술로 치료한 안면의 다발성 피부 Rosai-Dorfman Disease 1예
이진수 ( Jinsu Lee ),이기욱 ( Gi-wook Lee ),신준오 ( Jun-oh Shin ),노동영 ( Dongyoung Roh ),김연아 ( Yeona Kim ),원상현 ( Sang-hyeon Won ),이정수 ( Jungsoo Lee ),신기혁 ( Kihyuk Shin ),김훈수 ( Hoonsoo Kim ),고현창 ( Hyunchang Ko 대한피부과학회 2023 대한피부과학회지 Vol.61 No.10
Cutaneous Rosai-Dorfman disease (RDD) is a rare, benign condition mainly affecting the lymph nodes and sometimes involving the skin. RDD is notorious for its poor response to medication, and surgery is often the preferred treatment option for limited lesions. Herein, we present a case of cutaneous RDD in a 49-year-old woman with multiple facial nodules that showed minimal response to treatment with steroids, isotretinoin, and methotrexate. The diagnosis of cutaneous RDD was confirmed based on histopathological examination. The patient showed minimal response to medication; however, electrosurgery resulted in a relatively good cosmetic response. The present case demonstrates that electrosurgery can be an effective treatment option for cutaneous RDD, especially in case of patients with multiple lesions. The rarity of this disease and the limited reports on its management highlights the need for further research on the efficacy of different surgical modalities for cutaneous RDD. (Korean J Dermatol 2023;61(10):639∼642)